University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Faculty Publications in Food Science and
Technology

Food Science and Technology Department

8-14-2022

Characterizing isoform switching events in esophageal
adenocarcinoma
Yu Zhang
Katherine M. Weh
Connor L. Howard
Jean-Jack Riethoven
Jennifer Clarke

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/foodsciefacpub
Part of the Food Science Commons
This Article is brought to you for free and open access by the Food Science and Technology Department at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications in
Food Science and Technology by an authorized administrator of DigitalCommons@University of Nebraska Lincoln.

Authors
Yu Zhang, Katherine M. Weh, Connor L. Howard, Jean-Jack Riethoven, Jennifer Clarke, Kiran H. Lagisetty,
Jules Lin, Rishindra M. Reddy, Andrew C. Chang, David G. Beer, and Laura A. Kresty

Original Article

Characterizing isoform switching events
in esophageal adenocarcinoma
Yun Zhang,1,2 Katherine M. Weh,1,2 Connor L. Howard,1,2 Jean-Jack Riethoven,3,4 Jennifer L. Clarke,5
Kiran H. Lagisetty,1,2 Jules Lin,1,2 Rishindra M. Reddy,1,2 Andrew C. Chang,1,2 David G. Beer,1,2 and Laura A. Kresty1,2
1Department

of Surgery, Thoracic Surgery Section, University of Michigan, Ann Arbor, MI 48109, USA; 2Rogel Cancer Center, University of Michigan, Ann Arbor, MI

48109, USA; 3Nebraska Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA; 4Nebraska Center for Integrated Biomolecular
Communication, University of Nebraska-Lincoln, Lincoln, NE 68588, USA; 5Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln,
NE 68588, USA

Isoform switching events with predicted functional consequences are common in many cancers, but characterization
of switching events in esophageal adenocarcinoma (EAC) is
lacking. Next-generation sequencing was used to detect levels
of RNA transcripts and identify speciﬁc isoforms in treatment-naïve esophageal tissues ranging from premalignant
Barrett’s esophagus (BE), BE with low- or high-grade dysplasia
(BE.LGD, BE.HGD), and EAC. Samples were stratiﬁed by histopathology and TP53 mutation status, identifying signiﬁcant
isoform switching events with predicted functional consequences. Comparing BE.LGD with BE.HGD, a histopathology
linked to cancer progression, isoform switching events
were identiﬁed in 75 genes including KRAS, RNF128, and
WRAP53. Stratiﬁcation based on TP53 status increased the
number of signiﬁcant isoform switches to 135, suggesting
switching events affect cellular functions based on TP53 mutation and tissue histopathology. Analysis of isoforms agnostic,
exclusive, and shared with mutant TP53 revealed unique signatures including demethylation, lipid and retinoic acid
metabolism, and glucuronidation, respectively. Nearly half of
isoform switching events were identiﬁed without signiﬁcant
gene-level expression changes. Importantly, two TP53-interacting isoforms, RNF128 and WRAP53, were signiﬁcantly linked
to patient survival. Thus, analysis of isoform switching events
may provide new insight for the identiﬁcation of prognostic
markers and inform new potential therapeutic targets for EAC.

INTRODUCTION
Esophageal cancer is the seventh most common cancer worldwide
and one of the most lethal cancers.1 The two main subtypes of esophageal cancer include adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). Increasing incidence of EAC has been observed
throughout Westernized countries, including the United States,
United Kingdom, and Australia in recent years, whereas ESCC has
been declining with reduced tobacco use.2 EAC is the predominant
subtype of esophageal cancer in the United States and the seventh
leading cause of cancer-related deaths among US men.3 Moreover,
the 5-year survival rate following a diagnosis of EAC remains poor
at 19.9%.4 EAC is strongly associated with gastroesophageal reﬂux

disease (GERD), obesity, and male gender, and frequently develops
subsequent to long-standing Barrett’s esophagus (BE).5 BE is a metaplastic replacement of the normal squamous esophageal cells by
specialized columnar epithelium, usually resulting from chronic
GERD.5,6 BE represents the only known precursor lesion to EAC.7
Importantly, cancer risk and mutational burden increase with progression beyond BE metaplasia to BE with low-grade dysplasia
(LGD) and high-grade dysplasia (HGD).8,9 For BE patients with
LGD, the incidence rate of EAC is as low as 1.70% per patient-year,
whereas the incidence rate of EAC dramatically increases to 6.58%
per patient-year among BE patients with HGD.10 In addition, many
patients diagnosed with BE and HGD have occult EAC, further supporting the elevated risk associated with BE accompanied by
advanced pathologic changes.11 For these reasons, increasing our
understanding of the transition from low- to high-risk BE pathology
or BE with LGD to HGD and EAC may identify patterns of progression and in turn facilitate early detection and potentially a window for
intervention.
EAC is a cancer with one of the highest mutational burdens,12,13 but
unlike other similar cancers, the mutational burden is spread across a
large number of genes with relatively low mutational frequencies,
except for TP53.13–16 This coupled with the high spatial and temporal
heterogeneity of EAC has hampered clinical applications targeting
mutational drivers.17 Despite improved understanding of the
genomic landscape contributing to progression from BE to EAC in
recent years, we still have a poor understanding of how to leverage
this information for improved risk stratiﬁcation, or to inform targeted
strategies for esophageal cancer prevention and treatment. Thus, in
the current study we sought to move beyond single gene transcript
analysis to characterize differential alternatively spliced isoforms of
genes in esophageal tissues based on histological progression and
TP53 mutation status. This approach permits an investigation of
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Figure 1. Identification of significant isoform switching events with predicted functional consequences based on histopathology and TP53 status
(A) Number of isoform-switched genes detected in Barrett’s esophagus with metaplasia and low-grade dysplasia (BE.LGD) compared with BE with high-grade dysplasia
(BE.HGD) and with inclusion of TP53 mutation status, wild-type (WT) or mutant (MUT). (B) Top 10 GO processes identified for each comparison (p < 0.001 and FDR <0.001),
ranked by FDR value. (C) Volcano plot showing the differential isoform fraction (dIF) values comparing BE.LGD with BE.HGD. Each dot represents a transcript involved in isoform
(legend continued on next page)
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the individual splice variants or isoforms that contribute to gene
expression and in some cases reveals differentially expressed isoforms
masked by unchanged gene expression.
Historically, the lack of functional annotation of gene isoforms and
the dearth of sophisticated isoform analysis tools resulted in underutilization of RNA-sequencing (RNA-seq) data.18 More recently,
decreased sequencing costs coupled with increased availability of
next-generation sequencing platforms and advanced RNA-seq analysis tools have made transcriptomics quantiﬁcation with isoform resolution possible.19 Several recent investigations have performed isoform switch analysis using TCGA data revealing that isoform
switches are highly prominent in many cancers and can have profound biological impacts.18,20,21 To date, comprehensive analysis of
isoform switching has not been conducted in EAC or BE precursor
lesions. Herein, we investigated isoform switching events using
RNA-seq data collected from 57 esophageal tissue samples derived
from 46 treatment-naïve patients undergoing esophagectomy
following a diagnosis of HGD or EAC. Signiﬁcant isoform switching
events with predicted functional consequences were identiﬁed
comparing patients stratiﬁed by histopathology and TP53 mutation
status. Multiple studies link aberrant TP53 expression with malignant
progression of BE, particularly BE with HGD.22–26 Overall, TP53 mutation remains the strongest known driver of EAC progression,6 with
a mutation frequency over 70% in EAC patients.13 Incorporation of
TP53 mutation status in the analyses markedly increased detection
of isoform-switched genes and expression of speciﬁc isoforms linked
to TP53 were signiﬁcantly associated with patient survival. Gene
Ontology (GO) enrichment analysis of genes associated with differential isoforms revealed both shared and unique cancer relevant alterations when comparing BE with LGD to BE with HGD histology.
In turn, targeting identiﬁed processes may offer new leads for inhibiting BE progression. As proof-of-principle, we selected two novel
agents informed by the study results and evaluated efﬁcacy as inhibitors of EAC viability. Results indicate isoform switching events may
provide new molecular insights and potentially identify prognostic
markers or new therapeutic targets for EAC.

RESULTS
Isoform switching events and enrichment analysis based on
histologic progression and TP53

Isoform switching analysis was performed comparing patient tissues
categorized as BE with metaplasia and low-grade dysplasia (BE.LGD)
to BE high-grade dysplasia (BE.HGD), alone or with stratiﬁcation
based on TP53 mutation status as summarized in Figure 1. Patient demographic data and frequency of TP53 mutation for each group are
summarized in Table S1. When comparing BE.LGD with BE.HGD,

75 genes show signiﬁcant isoform switching events with predicted
functional consequences (Figure 1A). Moreover, with the inclusion
of TP53 mutation status, signiﬁcant isoform switching events
increased to 135 genes when comparing BE.LGD TP53 wild-type
(WT) with BE.HGD TP53 mutant (MUT). Next, GO pathway enrichment analysis was performed (Figures 1B, Tables S2, and S3)
revealing that most of the top enriched GO processes are shared between the two comparisons, with differences noted based on the signiﬁcance of ﬂavonoid metabolic process observed in BE.LGD versus
BE.HGD and retinoic acid metabolic process observed in BE.LGD
TP53 WT versus BE.HGD TP53 MUT. Dominant shared pathways
included processes related to glucuronidation and metabolism. For
BE.LGD versus BE.HGD, 14.7% (11 of 75) of top signiﬁcant isoform-switched genes have an absolute differential isoform fraction
(dIF) value greater than 0.25 (Figure 1C) and nearly all of the top
20 signiﬁcant genes involved in isoform switching are protein-coding
genes with the exception of MIR4458HG (Figure 1D). Similarly, when
comparing BE.LGD TP53 WT and BE.HGD TP53 MUT, 17.0% (23 of
135) of top signiﬁcant isoform-switched genes have an absolute dIF
value greater than 0.25 (Figure 1E) and again protein-coding genes
dominate, except for MIR4458HG and CENPBD1P1 (Figure 1F).
Among all identiﬁed isoform-switched genes, only isoform switching
of RNF128 was previously reported in HGD and EAC.27 Despite wellcharacterized gene-level changes in KRAS with EAC progression, isoform switching events were not previously reported.28–31 Additional
isoform switch events reported previously in other cancer targets
were also identiﬁed in our results, including TPM4 and
MINDY1.27,32–36 Isoform switching of TP53 is not observed in
BE.LGD TP53 WT versus BE.HGD TP53 MUT, potentially because
84.6% (22/26) of TP53 mutations are missense mutations failing to
result in further transcriptional level changes in TP53 isoforms (Figure S1). The high frequencies of missense TP53 mutations and mutation hotspots observed in our cohort align with previously published
studies in EAC.37–39 Signiﬁcant functional consequences associated
with dominant isoforms identiﬁed in BE.HGD and BE.HGD TP53
MUT include complete open reading frame (ORF) loss, signal peptide
loss, and the loss of protein-coding isoforms (Figure 1G). Global
splicing enrichment analysis also reveals that isoform switching
events are signiﬁcantly associated with changes in alternative transcription start sites (ATSS) and alternative transcription termination
sites (ATTS) in BE.LGD versus BE.HGD, and changes in alternative
50 splice site (A5) and ATTS in BE.LGD TP53 WT versus BE.HGD
TP53 MUT (Figure 1H).
In addition, gene set enrichment analysis (GSEA) on RNA- and
ribonucleoprotein (RNP)-related processes were performed on the
gene-level data, as well as differential gene expression analysis on

switching. In red are isoforms with |dIF| R 0.1 and FDR %0.05. (D) Dot plot showing top 20 genes with significant isoform switching events for BE.LGD versus BE.HGD. The shape
of each dot represents gene category and the color of each dot indicates significance level (|dIF| R 0.1 and FDR % 0.05). (E) Volcano plot showing dIF values in BE.LGD TP53 WT
versus BE.HGD TP53 MUT. Each dot represents a transcript involved in isoform switching. In red are isoforms with |dIF| R 0.1 and FDR %0.05. (F) Dot plot showing top 20 genes
with significant isoform switching events BE.LGD TP53 WT versus BE.HGD TP53 MUT (|dIF| R 0.1 and FDR % 0.05). (G) Dot plot showing functional consequences analysis
associated with isoform switching. (H) Dot plot showing global alternative splicing event analysis. The size of the dot indicates the number of isoform-switched genes in each
category and the line indicates 95% confidence interval. Significant changes in functional consequences and global alternative splicing events are colored in red (p % 0.05).
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RNA-binding proteins (RBPs), because of the role that RNPs and
RBPs play on alternative splicing.40,41 GSEA analysis indicates significant enrichment of alternative-splicing-associated pathways, such as
ribonucleoprotein complex biogenesis, spliceosomal small nuclear
RNP (snRNP) assembly, mRNA splice site selection, and regulatory
RNA binding (Figure 2A, Table S4, and S5). Sixty-one signiﬁcant
pathways were identiﬁed in BE.LGD versus BE.HGD, whereas 37 signiﬁcant pathways were identiﬁed in BE.LGD TP53 WT versus
BE.HGD TP53 MUT; thus, enriched pathways were more speciﬁc
in BE.LGD TP53 WT versus BE.HGD TP53 MUT (Table S4 and
S5). A strong upregulation of leading-edge genes in spliceosomal
snRNP assembly, mRNA splice site selection, spliceosomal complex
assembly, and regulatory RNA-binding pathways, as shown in
Figures 2B is observed in BE.HGD compared with BE.LGD patient
samples. Moreover, 54 and 73 RBPs are signiﬁcantly differentially expressed in BE.LGD versus BE.HGD and BE.LGD TP53 WT versus
BE.HGD TP53 MUT, respectively (Figures 2C and 2D). Among all
identiﬁed RBPs, 18.5% (10 of 54) and 28.8% (21 of 73) of RBPs had
predicted protein interactions with isoform-switched genes in
BE.LGD versus BE.HGD and BE.LGD TP53 WT versus BE.HGD
TP53 MUT, respectively. Taken together, both GSEA and differential
gene expression analysis revealed that expression changes of RNA
regulatory proteins and RBPs may contribute to observed isoform
switching events.
Last, qRT-PCR was used to validate isoform switching of RNF128,
KRAS, and TRIM29 using a subset of patients in the cohort (Figure S2). Isoform fractions using qRT-PCR results were comparable
to isoform fractions using RNA-seq data by the analysis tool.
Significant isoform switching events without differential gene
expression

Interestingly, 42.7% (32 of 75) of signiﬁcant isoform-switched genes
in BE.LGD versus BE.HGD (Table 1) and 45.9% (62 of 135) of genes
in BE.LGD TP53 WT versus BE.HGD TP53 MUT (Table 2) are not
differentially expressed on the gene level between the two conditions.
GO enrichment analysis was performed for isoform-switched genes
that occur in the absence of gene-level expression changes (Tables 1
and 2), with results closely paralleling those shown in Figure 1B
(data not shown). In brief, isoform switch analysis independent of
gene-level changes in BE.LGD versus BE.HGD supported top enriched biologic processes focused on hormone-related processes,
cellular glucuronidation, and histone and protein demethylation
and dealkylation processes. Similarly, isoform-switched genes identiﬁed in the comparison of BE.LGD TP53 WT versus BE.HGD TP53
MUT without gene-level alterations show GO biologic processes
overlapping with those in Figure 1B, but with less statistical signiﬁ-

cance likely due to reduced power with decreased sample numbers
(data not shown).
Moreover, several identiﬁed isoform-switched genes that do not show
overall differential gene expression have documented interactions
with TP53, including WRAP53, KDM6B, and TRIM29 (Figures 1D
and 1F, Tables 1 and 2, and Figure S3). These data highlight the potential impact of stratifying the isoform data by TP53 mutational status, as multiple isoform changes in TP53-related genes were identiﬁed
that otherwise would go undetected.
Isoform switching events unique or shared based on
stratification by pathology and TP53 status

Although a large overlap was observed in GO enrichment analysis
in BE.LGD versus BE.HGD (n = 75) compared with BE.LGD TP53
WT versus BE.HGD TP53 MUT (n = 135), the number of isoform
switching events nearly doubled when TP53 stratiﬁcation
was incorporated. Thus, a Venn diagram was generated to identify
shared and unique isoform-switched genes in the analysis as shown
in Figure 3A. Among all signiﬁcant genes in the analysis, 60
isoform-switched genes are shared between the two comparisons
(Figures 3A and Table S6), with 15 unique genes identiﬁed in
BE.LGD versus BE.HGD (Figures 3A and Table S7), and 75 genes
uniquely identiﬁed in BE.LGD TP53 WT versus BE.HGD TP53
MUT (Figures 3A and Table S8). As shown in Figure 3A, 80%
(60 of 75) of the isoform-switched genes in BE.LGD versus
BE.HGD are shared, whereas only 44.4% (60 of 135) of the isoform-switched genes in BE.LGD TP53 WT versus BE.HGD TP53
MUT are shared, supporting that greater numbers of unique alterations are associated with mutant TP53. Top signiﬁcant genes
in each section of the Venn diagram include many protein-coding
genes, but also several non-protein-coding genes including
SNHG18, AC009509, CADM3-AS1, MIR4458HG, CENPBD1P1,
and LINC02615 (Figures 3B–3D). Previously reported genes
involved in isoform switching (RNF128, TPM4, and KRAS)
were shared between the two comparisons, with the exception of
MINDY1, which was uniquely identiﬁed in BE.LGD TP53 WT
versus BE.HGD TP53 MUT.27,32–36 Next, GO enrichment analysis
of the non-overlapping isoforms in BE.LGD versus BE.HGD
and BE.LGD TP53 WT versus BE.HGD TP53 MUT comparisons
were conducted. For genes uniquely identiﬁed in BE.LGD versus
BE.HGD, top enriched processes are related to histone and protein
demethylation, dealkylation, and GDP catabolic process (Figure 3E
and Table S9). Top enriched processes based on genes unique in
BE.LGD TP53 WT versus BE.HGD TP53 MUT are more strongly
associated with lipid and alcohol metabolism, retinoic acid metabolism and biosynthesis, and midgut development (Figure 3E).

Figure 2. Changes associated with RNA regulatory proteins and RNA-binding proteins on the gene-level data
(A) GO pathway enrichments associated with RNA regulatory proteins identified in BE.LGD versus BE.HGD and BE.LGD TP53 WT versus BE.HGD TP53 MUT
(p-value % 0.05 and FDR %0.25). Pathways are colored and ranked by FDR. (B) Heatmap of the leading-edge genes identified in select pathways in the GO pathway
enrichment analysis. Dot plot on the right shows the pathways that the gene belongs. (C) Volcano plot of the expression of RNA-binding proteins (RBPs) in BE.LGD versus
BE.HGD. (D) Volcano plot of the expression of RBPs in BE.LGD TP53 WT versus BE.HGD TP53 MUT. Red dot represents significantly differentially expressed RBPs (|
log2FC| > 0.585 and FDR %0.05). Gene names of the genes that interact with isoform-switched genes predicted by the STRING database are shown.
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Table 1. Significant isoform switching events without altered gene expression in BE.LGD versus BE.HGD
Gene name
MIR4458HG

RPL22L1

AC234782.4

SLC25A35

ZNF350

SNHG18

TMEM104
COX19
WRAP53
DISP2
LINC02542
NEU4
AC093866.1
GDF15

Isoform ID

dIF

FDR

ENST00000502001

0.326

<0.001

ENST00000652260

0.355

<0.001

ENST00000463836

0.149

<0.001

ENST00000475836

0.124

<0.001

ENST00000674488

0.259

<0.001

KDM6B
AC103810.1
PCSK5

ENST00000674271

0.248

0.024

ENST00000581320

0.152

0.009

ENST00000577745

0.131

0.025

ENST00000243644

0.138

0.009

ENST00000599258

0.125

0.013

RBP2

ENST00000508179

0.157

0.010

AC009509.2

ENST00000655411

0.246

0.015

UGT2B7

ENST00000335464

0.182

0.011

GHR

ENST00000584246

0.119

0.016

ENST00000466146

0.117

0.012

AC073896.1

Isoform ID

dIF

FDR

ENST00000254846

0.123

0.020

ENST00000575521

0.146

0.039

ENST00000585187

0.201

0.021

ENST00000376752

0.134

0.022

ENST00000674117

0.147

0.023

ENST00000548360

0.125

0.023

ENST00000549318

0.124

0.024

ENST00000615289

0.195

0.023

ENST00000367027

0.199

0.029

ENST00000511956

0.267

0.024

ENST00000536922

0.229

0.026

ENST00000305231

0.217

0.026

ENST00000537449

0.147

0.026

SLC2A5

ENST00000484798

0.219

0.031

AP000866.2

ENST00000504932

0.163

0.033

ENST00000415675

0.128

0.033

ENST00000609696

0.128

0.035

HSD11B1

ENST00000316024

0.126

0.014

ENST00000396463

0.154

0.040

ENST00000559721

0.230

0.014

RSPH1

ENST00000291536

0.101

0.038

ENST00000660534

0.195

0.019

CFAP46

ENST00000486104

0.132

0.041

CADM3-AS1

ENST00000668266

0.120

0.042

CA4

ENST00000585705

0.147

0.041

ENST00000407683

0.239

0.019

CNTN1

ENST00000347616

0.167

0.047

RTN2

ENST00000245923

0.105

0.048

ENST00000613958

0.108

0.049

ENST00000611621

0.108

0.049

ENST00000513572

0.153

0.019

ENST00000612706

0.102

0.028

ENST00000252809

0.145

0.020

For genes shared between the two comparisons in the overlapping
section of the Venn diagram, GO enriched processes are similar to
the previous analysis (Figure 1B) with top processes related to
glucuronidation and metabolism (Figures 3E and Table S10).
Although enriched processes had a signiﬁcant p-value (%0.05),
none of the enriched processes unique to BE.LGD TP53 WT versus
BE.HGD TP53 MUT reached a signiﬁcant false discovery
rate (FDR) %0.05, but instead ranged from 0.08 to 0.16, suggesting
greater heterogeneity of isoform-enriched genes in that grouping.
TP53-linked isoform changes correspond to patient outcomes

TP53 is the strongest known genetic driver of EAC with a mutation
frequency of over 70% in EAC patients.8,13 In turn, isoformswitched genes with direct interaction with TP53 were identiﬁed
using the STRING database (Figure S3). Patient survival was also
determined to investigate whether there is an association between
expression of speciﬁc isoforms of TP53-linked genes and survival
among EAC patients.
Isoform switching of RNF128 was recently reported to show
decreased expression of RNF128-202 and increased expression of
RNF128-201 contributing to the stabilization of mutant TP53 and
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potentially EAC progression.27 Our analysis conﬁrms the RNF128
isoform-switching event with similar trends observed (Figure 4A).
The overall expression of RNF128 is signiﬁcantly lower in patients
with BE.HGD compared with patients with BE.LGD and isoform usage of each isoform is signiﬁcantly altered, supporting the isoform
switching event. Functional domain prediction using Pfam did not
reveal any major changes in protein domains. However, a signiﬁcant
difference in patient survival was observed in the analysis (Figure 4B).
Patients with higher expression levels of RNF128-202 had a signiﬁcantly higher survival probability compared with patients with lower
expression of the same isoform (Wilcoxon p-value = 0.031). Patient
samples with high expression of RNF128-202 were largely composed
of BE.LGD samples with only one BE.HGD and one EAC patient
sample, whereas tissues with low expression levels of RNF128-202
were contributed by either BE.HGD or EAC samples.
WRAP53 is another isoform-switched gene with direct TP53 interactions (Figure S3). WRAP53 transcripts with exon regions overlapping
with the TP53 exon are believed to be the antisense of TP53,
which can result in TP53 induction.42 On the gene level, signiﬁcant
expression differences were not observed in WRAP53 between
BE.LGD and BE.HGD patient samples. However, on the isoform level,

www.moleculartherapy.org

Table 2. Significant isoform switching without altered gene expression in BE.LGD TP53 WT versus BE.HGD TP53 MUT
Gene name
MIR4458HGa

MINDY1

EVI2B

CENPBD1P1

AC234782.4a

LINC02615

TSPAN6

SMIM6
SESN1
TMED1
AC026254.2
LINC00964

TMEM241

PLA2G15
ANKRD54
ZNF350a

Isoform ID

dIF

FDR

Gene name

Isoform ID

dIF

FDR

ENST00000502001

0.326

<0.001

NEU4a

ENST00000407683

0.239

0.019

ENST00000652260

0.355

<0.001

FSIP2-AS1

ENST00000429929

0.152

0.019

ENST00000361936

0.135

<0.001

AC015802.4

ENST00000592622

0.200

0.019

ENST00000470877

0.100

<0.001

ALDH1A2

ENST00000558239

0.110

0.019

ENST00000330927

0.108

<0.001

PTRH1

ENST00000543175

0.202

0.019

ENST00000577894

0.108

<0.001

ENST00000196482

0.136

0.020

ENST00000493504

0.103

<0.001

ENST00000593925

0.126

0.034

ENST00000651608

0.117

<0.001

GDF15a

ENST00000252809

0.145

0.020

ENST00000674488

0.259

<0.001

AC103810.1a

ENST00000585187

0.201

0.021

ENST00000674271

0.248

0.024

ENST00000376752

0.134

0.022

ENST00000505133

0.110

<0.001

ENST00000674117

0.147

0.023

ENST00000513851

0.157

0.024

ENST00000494424

0.114

<0.001

ENST00000614008

0.108

0.021

LTB4R2

ENST00000527924

0.108

0.023

ENST00000556126

0.116

0.001

CRYBA2

ENST00000392096

0.202

0.024

ENST00000579469

0.116

0.001

GHRa

ENST00000537449

0.147

0.026

ENST00000436639

0.133

0.001

ENST00000545238

0.240

0.028

ENST00000588289

0.103

0.002

ENST00000372518

0.240

0.029

ENST00000214869

0.113

0.019

ENST00000476085

0.137

0.028

ENST00000666005

0.220

0.003

ENST00000657752

0.128

0.005

ENST00000663940

0.107

0.009

ENST00000577448

0.100

0.005

ENST00000475185

0.128

0.029

ZNF324

PCSK5a

DCDC2

NEURL2

MSH5-SAPCD1

TNNI1

SFTA2

ENST00000378454

0.174

0.022

ENST00000378450

0.177

0.025

ENST00000493662

0.106

0.031

ENST00000622580

0.180

0.029

ENST00000555340

0.164

0.043

ENST00000634371

0.113

0.030

ENST00000359086

0.106

0.037

ENST00000562966

0.103

0.006

CCDC170

ENST00000537358

0.269

0.030

ENST00000219345

0.115

0.044

TLCD1

ENST00000292090

0.153

0.031

ENST00000609706

0.125

0.006

SOCS4

ENST00000395472

0.121

0.031

ENST00000243644

0.138

0.009

AP000866.2a

ENST00000504932

0.163

0.033

ENST00000599258

0.125

0.013

C1orf53

ENST00000436652

0.147

0.033

GAS2

ENST00000278187

0.155

0.009

TRIM29

ENST00000532195

0.122

0.036

ATP9B

ENST00000586722

0.115

0.009

ENST00000470448

0.118

0.011

ENST00000491809

0.186

0.048

RSPH1a

ENST00000291536

0.101

0.038

ENST00000335464

0.182

0.011

CARNS1

ENST00000307823

0.190

0.040

ENST00000584246

0.119

0.016

CFAP46a

ENST00000486104

0.132

0.041

ENST00000466146

0.117

0.012

CA4a

ENST00000585705

0.147

0.041

SPATA17

TMEM104a
COX19a
WRAP53a
DISP2a
BCL7A

AC117453.1

EFHC2

ENST00000420999

0.221

0.037

ENST00000343571

0.221

0.038

ENST00000316024

0.126

0.014

ONECUT1

ENST00000305901

0.219

0.043

ENST00000396463

0.154

0.040

LINC00278

ENST00000652068

0.135

0.043

ENST00000559721

0.230

0.014

TMEM107

ENST00000437139

0.106

0.045

ENST00000432926

0.197

0.015

ENST00000622512

0.102

0.046

ENST00000261822

0.160

0.039

ENST00000358704

0.102

0.047

ENST00000651749

0.182

0.016

RTN2a

ENST00000245923

0.105

0.048

ENST00000656199

0.151

0.021

LINC01186

ENST00000670979

0.115

0.049

ZBTB18

(Continued on next page)
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Table 2. Continued
Gene name
SYT15

S100A5

Isoform ID

dIF

FDR

Gene name

Isoform ID

dIF

FDR

ENST00000449358

0.138

0.017

CCDC190

ENST00000524710

0.139

0.050

ENST00000374321

0.131

0.026

ENST00000368717

0.247

0.017

ENST00000368718

0.247

0.020

a

Genes shared between BE.LGD versus BE.HGD and BE.LGD TP53 WT versus BE.HGD TP53 MUT. BE.LGD: Barrett’s esophagus with metaplasia or low-grade dysplasia; BE.HGD:
Barrett’s esophagus with high-grade dysplasia.

a signiﬁcant increase of WRAP53-201 and a decrease of WRAP53-202
are observed (Figure 4C). The 50 -UTR of WRAP53-201 contains a
shared region with the ﬁrst exon of TP53, whereas WRAP53-202 does
not have any overlapping regions. Moreover, patients with high expression levels of WRAP53-201 have a signiﬁcantly lower survival probability compared with patients with low expression levels of WRAP53-201
(Figure 4D; Wilcoxon p-value = 0.050). All high-expressing patient
samples were either BE.HGD or EAC, whereas low-expressing samples
were contributed by BE.LGD tissues. Still, two BE.HGD patient samples
and one EAC sample had low WRAP53-201 expressions, suggesting
isoform expression level is not solely determined by histopathological
progression.
In addition, survival differences based on histopathological categorization were calculated to evaluate the possibility that signiﬁcant differences in patient survival were solely driven by the histopathological
distribution. The survival probability of patients with BE.HGD is
marginally lower than the survival probability of BE.LGD patients
(Figure 4E; Wilcoxon p-value = 0.113) and when EAC samples are
included in the analysis, the survival probability is also marginally lower
and borderline statistically signiﬁcant (Figure 4F; Wilcoxon
p-value = 0.058). Ultimately, these results support that isoform switching events may reveal speciﬁc gene isoforms that impact patient survival
to a greater extent than histopathological changes alone and speciﬁc isoforms may be targetable as novel targets for prevention or treatment.
Isoform switching informs targetable processes for EAC
inhibition

Our results revealed that mutant TP53 increases isoform switching
events and modulates numerous lipid and retinoic acid-linked processes including unique changes in 9-cis-retinoic acid, leading us
to evaluate the inhibitory potential of two Food and Drug Administration (FDA)-approved and mechanistically relevant pharmacological agents for targeting EAC. TP53 MUT EAC cells (OE33 and
JHAD1) were treated with adapalene,43 an agonist of the retinoic
acid receptor (RAR) b and g, and the mutant TP53 targeting agent
APR-246.44 These two drugs were selected as proof-of-concept
agents given identiﬁcation of 9-cis-retinoic acid metabolic processes and retinoic acid biosynthetic processes in the comparison
of BE.LGD TP53 WT versus BE.HGD TP53 MUT (Figure 3E).
Gene-level GSEA reveals signiﬁcant downregulation of retinol
metabolism in BE.HGD TP53 MUT patients compared with
BE.LGD TP53 WT (Figure S4), suggesting that activation of reti-
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noic acid signaling may elicit anti-cancer activity targeting EAC.
Therefore, adapalene was used to test whether stimulating retinoic
acid signaling in TP53 MUT EAC cell lines would induce EAC cell
death. Both OE33 and JHAD1 cells show dose-dependent inhibition of viability following adapalene treatment with the lethal
dose 50 (LD50) in the 1.5- to 2.0-mM range (Figures 5A–5D). At
72 h post-treatment, 1.5 mM adapalene signiﬁcantly decreases
OE33 cell viability to 42.59% (Figures 5A and 5B). Similarly, at
72 h, 2.0 mM adapalene treatment signiﬁcantly decreases JHAD1
cell viability to 41.50% (Figures 5C and 5D). Importantly, OE33
cells treated with adapalene do not recover following treatment
removal (Figures S5A and S5B). However, JHAD1 cells do show
recovery upon adapalene removal, suggesting adapalene is only
inhibitory in JHAD1 cells when present, with little durable effect
once removed (Figures S5C and S5D). Thus, a combination of
agents may prove more efﬁcacious in JHAD1 cells.
Next, APR-246, a small molecule agent that restores TP53 WT
functions in TP53 MUT cells by covalently binding to cysteine
residues in TP53 MUT cells,44 was evaluated. TP53 mutation is a
well-known driver for EAC progression and several isoformswitched genes have direct interactions with TP53 (Figure S3).
OE33 and JHAD1 cells were treated with various concentrations
of APR-246. APR-246 treated OE33 cells show a dose-dependent
response with an LD50 above 20 mM, but clearly less than
40 mM, which permanently induces cell death (Figures 5E, 5F,
S5E, and S5F). At 72 h, 20 mM APR-246 treatment signiﬁcantly
decreased OE33 cell viability to 62.84% and 40 mM APR-246 treatment signiﬁcantly decreased OE33 cells viability to 8.57%. OE33
cells treated with 40 mM APR-246 do not recover upon treatment
withdrawal (Figures S5E and S5F). For JHAD1 cells, a sharp
decrease in cell viability was observed between 20 mM and 40
mM treatments. At 72 h, 20 mM APR-246 treatment signiﬁcantly
decreases cell viability to 64.61%, whereas 40 mM treatment
completely eradicates JHAD1 cells (Figures 5G and 5H). JHAD1
cells did recover following drug removal when lower concentrations of APR-246 were utilized (<40 mM; Figures S5G and S5H).
Representative ﬂuorescent images from the viability assays performed in OE33 and JHAD1 cells show decreases in viability
from adapalene (Figures 5B and 5D) and APR-246 (Figures 5F
and 5H). Collectively, these results conﬁrm that targeting the retinoic acid and TP53 pathways using pharmacological agents is
successful in inducing EAC cancer cell death, and that evaluations
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of mechanistically driven combinations are warranted to screen
for enhanced durable effects. These data further validate the
identiﬁcation of pathways based on isoform-switching analysis using RNA-seq datasets.

DISCUSSION
In this study, we performed isoform switch analyses using an RNA-seq
dataset composed of 57 esophageal tissues across a continuum of pathologies ranging from BE with metaplasia, to BE with dysplasia
(both low and high grade), and EAC. Isoform switch analyses were conducted based on histopathological progression and TP53 mutation status given its key role in EAC progression. Our goal was to characterize
isoform switching events in EAC and understand whether factors associated with increased risk for progression to EAC, namely the presence
of HGD or mutant TP53, show unique isoform switching events that
may inform future risk stratiﬁcation, prevention, or therapeutic efforts.
Seventy-ﬁve genes involved in isoform switching were identiﬁed
comparing low-risk with high-risk histopathologies or BE.LGD with
BE.HGD groups. Inclusion of TP53 mutation status coupled with histopathological stratiﬁcation markedly increased the number of isoform-switched genes identiﬁed, resulting in 135 genes. Previously published studies suggest that alternative splicing is performed by
spliceosomes and could also be controlled by RBPs, both of which are
crucial components of various ribonucleoprotein (RNP) complexes.40,41 In our data, gene-level GSEA analysis revealed many significantly enriched processes related to alternative splicing in BE.HGD
compared with BE.LGD and in BE.HGD TP53 MUT compared with
BE.LGD TP53 WT patient samples, such as ribonucleoprotein complex
biogenesis, spliceosomal snRNP assembly, mRNA splice site selection,
and spliceosomal complex assembly as evidenced by strong upregulation of genes in these pathways in BE.HGD compared with BE.LGD
patient samples (Figure 2). For example, small nuclear ribonucleoprotein D1/2 polypeptide (SNRPD1 and SNRPD2) were two of the leadingedge genes identiﬁed in both spliceosomal snRNP assembly and spliceosomal complex assembly pathways. Previously published studies
suggest that overexpression of SNRPD1 and SNRPD2 are common
in many cancers, leading to abnormal alternative splicing and regulating cell cycle and autophagy.45,46 In EAC, TP53 mutation is the
most commonly observed mutation, with a mutation frequency over
70%.13 TP53 mutation is not only a driver mutation contributing
to the EAC progression, but TP53 mutations also contribute to alternative splicing activity in cancer.47 In pancreatic ductal adenocarcinoma
(PDAC), TP53 mutations lead to signiﬁcant exon usage changes
and upregulate expression of RNA processing factors important for
RNA splicing.47 Therefore, aberrant RNA splicing machinery activity
resulting from TP53 mutation may explain why more isoform-switched
genes are observed in the comparison of BE.LGD versus BE.HGD with
the incorporation of TP53 mutation status. Aside from signiﬁcant

pathway enrichment of alternative-splicing-related processes, multiple
RBPs are differentially expressed on the gene level. The number
of signiﬁcantly altered RBPs identiﬁed are markedly increased
when TP53 mutation status is incorporated in the analysis and several
RBPs have protein interactions with identiﬁed isoform-switched
genes (Figures 2C and 2D). Our data support the merit of delineating
speciﬁc interactions between RBPs and isoform-switched genes
in future research samples using cross-linking-immunoprecipitationsequencing. Global functional consequence analysis revealed three
shared signiﬁcant changes between BE.LGD versus BE.HGD and
BE.LGD TP53 WT versus BE.HGD TP53 MUT, which are the loss of
ORFs, signal peptide, and coding transcript, suggesting that dominant
isoforms observed in BE.HGD, regardless of TP53 mutation status, will
have profound impact on related cellular functions, which might also be
contributing factors for EAC progression.
Comprehensive analysis of isoform switching events has not previously
been performed in BE or EAC. A previous pan-cancer analysis utilizing
the Pan-Cancer Analysis of Whole Genomes included seven EAC cases
reporting isoform-related changes in only one EAC patient when
compared with non-patient-matched normal esophageal tissues from
Genotype-Tissue Expression (GTEx), presenting ﬁndings as “most
dominate transcripts,” not isoform switching events making generalizability uncertain.48 In addition, isoform switching of RNF128 was previously reported in HGD and EAC.27 RNF128 encodes an E3 ubiquitin
ligase responsible for the degradation of TP53. Similarly, we show that
RNF128 undergoes isoform switching in patients with BE.LGD
compared with BE.HGD, with increased expression of RNF128-201
and decreased expression of RNF128-202. RNF128-201 has limited
ubiquitin ligase activity and fails to degrade mutant TP53, whereas
RNF128-202 is the main isoform responsible for TP53 degradation.27
Importantly, we observed a signiﬁcant patient survival advantage
among RNF128-202 high expressors compared with low expressors.
In addition, patients with high expression levels of RNF128-201 had
a non-signiﬁcantly lower survival probability compared with patients
with low expression levels (data not shown).
With the exception of RNF128, isoform switching events have been
largely unexplored in BE and EAC. Herein, we identify large numbers
of events linked to advanced pathology, as well as TP53 mutation (as
detailed in Tables S6, S7, and S8). Two reports characterizing isoform
switching events in ESCC identiﬁed numerous unique isoforms with
only MINDY1 as a gene in common with our isoform switch analysis,
supporting divergent molecular changes based on esophageal cancer
subtype.36,49 MINDY-1, also known as FAM63A, is a newly identiﬁed
deubiquitinating protein that preferentially removes K48-linked
ubiquitin molecules.50 In BE and EAC, MINDY1 was identiﬁed in a
set of 90 genes signiﬁcantly predicting disease progression by distinguishing EAC progressors from patients with non-dysplastic BE.51

Figure 3. GO processes associated with significant isoform switching based on histopathology and TP53 mutation status
(A) Venn diagram showing 15 unique genes involved in isoform switching in BE.LGD versus BE.HGD, 75 unique genes involved in isoform switching in BE.LGD TP53 WT
versus BE.HGD TP53 MUT, and 60 genes shared. (B–D) Top 10 most significant isoform-switched genes in each section of the Venn diagram (|dIF| R 0.1 and FDR % 0.05).
(E) GO enrichment analyses showing the top 10 enriched biological processes in each part of the Venn diagram (p < 0.01).
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Figure 4. TP53-linked isoform switches predict patient survival
(A) Isoform switching of RNF128. Transcripts involved in isoform switching of RNF128 and their predicted functional domain Error bars indicate 95% confidence intervals and
significance levels of isoform usage were determined by the Mann–Whitney U test (* FDR % 0.05). (B) Kaplan-Meier survival curve of patients stratified by expression level of
RNF128 transcript ENST00000324342 and the histology proportion of patients in each group. (C) Isoform switching of WRAP53. Transcripts of WRAP53 and their
(legend continued on next page)
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Moreover, MINDY-1 was found to promote bladder cancer progression by stabilizing YAP,52 a key tumorigenesis pathway member that
can also be induced by conjugated bile acids in EAC.53 In our analysis,
increased usage of the MINDY1 transcript that lacks deubiquitinase
(DUB) domains and a decreased usage of the MINDY1 transcript
that contains ﬁve DUB domains are observed, potentially suggesting
impaired MINDY-1 function during EAC progression. Despite the
fact that the MINDY1 transcripts involved in isoform switching are
different in our analysis than the data published in ESCC,36 a similar
switching trend is observed in that the isoform transcript that does
not contain DUB domains is increased while the usage is decreased
for a DUB domain-containing transcript. These data suggest that
MINDY1 isoforms lacking deubiquitinase domains may be important
for both EAC and ESCC progression.
In ESCC, reported isoform switching events were dominated by cell
regulation of cell motility, cell-to-cell junction organization, regulation of cell migration, and adhesion-linked GO processes.49 Select isoform-switched genes in our BE progression dataset hold some similar
functions. For example, isoform switching of TPM4 was originally
observed in breast cancer with loss of TPM4.1 associated
with increased migration, disruption of cell-cell adhesions, and cancer
invasiveness.32 Moreover, TPM4.1 inhibited cellular invasion by regulating the Rac1-myosin IIB signaling.32 Signiﬁcant decreases in
TPM4.1 are observed when comparing BE.LGD with BE.HGD patients, and thus loss of TPM4.1 during EAC progression may
contribute to invasive cell behavior.32
Ampliﬁcation and mutation of KRAS have been previously reported in
EAC.30,54,55 Despite the mutation frequency of KRAS in EAC being less
than 20%, it is considered an EAC driver and proposed targeting
of KRAS mutations may sensitize a subgroup of EAC patients to
targeted treatment.30 Alternative splicing of KRAS is well documented
in other cancers,33,35,56–60 resulting in two isoforms, KRAS4A and
KRAS4B,33 both of which can carry KRAS mutations.33 Although
expression of both KRAS4A and KRAS4B has been observed in
cancer,58 KRAS4B is thought to be more tumorigenic than KRAS4A.33
KRAS4A expression inhibits apoptosis, whereas KRAS4B does not.57
KRAS4B also regulates the matrix metalloproteinase MMP-2, which
is linked to esophageal cancer development, via the PI3K-AKT
signaling pathway.56,61 Moreover, in colorectal carcinoma, expression
of KRAS4B was found to be signiﬁcantly associated with larger tumor
size while expression of KRAS4A was signiﬁcantly associated with better patient survival.35 In our isoform switching analysis and qRT-PCR
validation, we observed increased expression of KRAS4B and decreased
expression of KRAS4A, suggesting that KRAS4B may exert a similar
oncogenic role in EAC progression and warrant investigation as a therapeutic target (Figures S2C and S2D).

Interestingly, isoform switch analysis in this study also identiﬁed
signiﬁcant isoform-switched genes without signiﬁcant differences in
gene-level expression (Tables 1 and 2). Thirty-two isoform switching
events (32 of 75, or 42.7%) were identiﬁed in comparing BE.LGD with
BE.HGD, whereas BE.LGD TP53 WT compared with BE.HGD TP53
MUT resulted in identiﬁcation of 62 isoform switching events (62 of
135, or 45.9%) without overall gene expression changes. GO enrichment analysis revealed similar enriched biological processes for those
genes compared with enrichment analysis of all isoform-switched
genes (data not shown). Isoform-switched genes that occur in the
absence of altered gene-level expression include KDM6B, UGT2B7,
WRAP53, and TRIM29. KDM6B, also known as lysine-speciﬁc demethylase 6B, is a histone demethylase that can act as either a tumor
suppressor or oncogene in cancer.62 KDM6B is reportedly overexpressed in pancreatic premalignancy with its expression decreasing
with progression to PDAC, supporting a role for KDM6B in pancreatic carcinogenesis.63 Although overall expression differences were
not signiﬁcant between patients with BE.LGD compared with
BE.HGD, expression of the KDM6B coding transcript decreased while
the expression of the non-coding transcript increased, suggesting
KDM6B might also be important during early EAC progression.
Conversely, KDM6B has been shown to promote ESCC progression
and KDM6B levels signiﬁcantly increased in patients with lymph
node metastasis.64
As highlighted in Figure 3, the Venn diagram depicts all signiﬁcant isoform-switched genes and reveals common and unique isoform switching events based on histopathology alone or both histopathology and
TP53 mutation status. Subsequent enrichment analysis revealed common and unique changes in GO biologic processes based on stratiﬁcation by histopathology and TP53 mutation status. Multiple biologic
processes related to glucuronidation were among the top signiﬁcantly
enriched GO processes shared between two comparisons, primarily
caused by signiﬁcant isoform switching events observed in UGT1A1
and UGT2B7. In recent years, multiple studies have shown that
UDP-glucuronosyltransferase enzymes (UGTs) are linked to increased
cancer risk, drug resistance, and cancer progression.65,66 Multiple casecontrol studies have been published identifying associations between
UGT polymorphisms and cancer risk.65,66 It is hypothesized that
UGT polymorphisms can decrease glucuronidation of carcinogens
and molecules that promote cancer, such as estrogens, dietary carcinogens, and tobacco carcinogens, resulting in cancer progression.65,67–72
However, studies have not found a signiﬁcant association between
UGT polymorphisms and EAC risk.73 Based on our analysis, we identiﬁed a signiﬁcant increase in the usage of a UGT1A1 isoform that lacks
a UDP-glucuronosyl and UDP-glucosyl transferase (UDPGT) domain,
suggesting there is decreased glucuronidation activity of UGT1A1.
Moreover, isoform switching results of UGT2B7 showed a signiﬁcant

corresponding isoform usage. Error bars indicate 95% confidence intervals and significance levels of isoform usage were determined by the Mann–Whitney U test, ns indicates no significant change, (* FDR % 0.05). (D) Kaplan-Meier survival plot of patients stratified by expression of WRAP53 transcript ENST00000316024 and histology
distribution of patients in each group. (E) Survival probability of BE.LGD or BE.HGD patient samples (n = 32). (F) Patient survival probability of BE.LGD or BE.HGD + EAC (n =
41). Only the most severe pathological sample for each patient was kept in the analysis if a patient contributed multiple biopsy samples. Significance of survival differences
was calculated by the Gehan-Breslow-Wilcoxon test.
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Figure 5. Enrichment analysis of isoform switching events supports retinoic acid and TP53 signaling pathway targeting to inhibit EAC growth
(A) Viability of adapalene-treated OE33 cells measured using Calcein-AM staining 48 and 72 h post-treatment with (B) representative fluorescent images of adapalene-treated
Calcein-AM stained OE33 cells. (C) Viability of adapalene-treated JHAD1 cells assessed using Calcein-AM 48 and 72 h post-treatment with (D) representative fluorescent
images of adapalene-treated stained JHAD1 cells. (E) Viability of OE33 cells treated with APR-246 at 48 and 72 h post-treatment with (F) representative fluorescent images of
stained OE33 cells treated with APR-246. (G) Viability of JHAD1 cells treated with APR-246 at 48 and 72 h post-treatment with (H) representative fluorescent images of
stained JHAD1 cells treated with APR-246. Significant differences of viability were assessed by ANOVA with Tukey’s post hoc test for multiple comparisons between
treatments. Within each time point, treatments were significantly different from a = vehicle (VEH), b = 1.0 mM adapalene or 10 mM APR-246, c = 1.5 mM adapalene or 20 mM
APR-246, and d = 2.0 mM adapalene or 40 mM APR-246. Data are shown as mean ± standard error. Note: VEH-48h and VEH-72h images are the same in 5B and 5F because
adapalene and APR-246 treatment of OE33 cells occurred in the same plate to permit direct comparisons. Similarly, VEH-48h and VEH-72h images are the same in 5D and
5H for JHAD1 cells. Scale bars, 500 mm.
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decrease in expression of the isoform that encodes a UDPGT domain,
which also suggests impairment of UGT2B7 glucuronidation activity in
EAC progression.

overlap with exons of TP53.42 In the isoform switching analysis,
we observed increased expression of a WRAP53 transcript with an
overlapping exon region with TP53 and decreased expression of a
WRAP53 transcript that does not contain an overlapping region.
Moreover, protein functional domains predicted by Pfam are the
same between these two isoforms. Based on this, we speculate
that increased expression of a transcript with an overlapping region
of TP53 may induce expression of mutant TP53 contributing to disease progression; however, such switching events are not likely to
have a profound impact on WRAP53 function since the functional
domains remain unchanged.

In addition, enrichment of processes related to demethylation from
isoform-switched genes uniquely observed in the comparison of
BE.LGD versus BE.HGD were detected. Demethylation processes in
EAC have been extensively studied, and previous studies identiﬁed
a key role for demethylation during disease progression, including
promoter demethylation for chemokine genes and upregulation of
histone demethylation proteins (KDM4C and KDM6A).74,75 Isoform
switch analysis and GO biological process enrichment analysis identiﬁed KDM5A and KDM5B as the main genes contributing to the
observed enrichment of demethylation process, both of which have
oncogenic roles in ESCC development but have not been assessed
in EAC.64,76 For GO processes uniquely enriched in BE.LGD TP53
WT versus BE.HGD TP53 MUT, processes related to retinoic acid
biosynthesis and 9-cis-retinoic acid biosynthesis were identiﬁed (Figure 3E). Gene-level analysis revealed downregulation of associated
genes with GSEA showing downregulation of retinol metabolism in
patients with BE.HGD TP53 MUT (Figure S4). Isoform switching
analysis of retinol dehydrogenase 5 (RDH5) and aldehyde dehydrogenase 1 family member A2 (ALDH1A2), key proteins in the 9-cis-retinoic acid biosynthesis, revealed downregulation of both RDH5 and
ALDH1A2 coding transcripts, while expression levels of non-coding
transcripts were increased, further suggesting decreased activity
of such processes (Table S8). Downregulation of RDH5 has been reported in multiple types of cancer, including hepatocellular carcinoma, colon adenomas and carcinomas, and thyroid carcinoma.77–79
In hepatocellular carcinoma, RDH5 was found to suppress proliferation and metastasis by reversing epithelial-mesenchymal transition.79
Downregulation of ALDH1A2 was also reported in several cancer
types and suggest to act as a tumor suppressor.80,81 Studies have
also pointed out that cancer cells treated with 9-cis-retinoic acid
induce apoptosis and inhibit cancer cell growth both in vitro and
in vivo.82,83 Moreover, retinoic acid receptor RARb, was shown to
act as a tumor suppressor in lung cancer.84 In BE patients with
LGD or HGD, expression of both RARb and RARg are signiﬁcantly
lower compared with normal esophageal tissues, and the retinoic
acid-regulated nuclear protein regulation pathway is the most significantly enriched pathway in EAC progressors compared with patients
with non-dysplastic BE, suggesting the potential role of retinoic acidrelated processes in EAC progression.51,85

The Venn diagram and subsequent GO biological process analysis in
Figure 3 show differences in pathway enrichment based on pathology
and TP53 mutation status, suggesting that patients stratiﬁed into
different subgroups may potentially beneﬁt from different treatment
regimens. As a proof-of-principle, we used two FDA-approved drugs
that target the 9-cis-retinoic acid pathway and TP53 mutation to test
this hypothesis. Two EAC cell lines, OE33 and JHAD1, were treated
with the RARb and RARg agonist, adapalene, and results indicated
that adapalene was a potent inducer of cell death in both cell lines.
Considering RARb and RARg are two of the receptors of 9-cis-retinoic acid, these data suggest activation of 9-cis-retinoic acid pathway
may hold potential for targeting EAC.86 Moreover, to test the potential beneﬁt of blocking mutant TP53 expression in EAC, OE33 and
JHAD1 cells (both TP53 mutant) were treated with APR-246, a small
molecule that restores TP53 WT functionality.44 Results showed that
post-treatment with APR-246, both EAC cell lines experienced
signiﬁcant loss of viability, which is in alignment with previously published results in EAC and ESCC, although a discrepancy in effective
treatment concentration of OE33 cell was noticed.87,88 Therefore,
treatment with APR-246 suggests that inhibition of mutant TP53
expression and isoform expression linked to mutant TP53 may be a
viable preventive or treatment approach for inhibiting EAC. Moreover, enrichment of the lipid metabolism process is also observed
in our analysis for BE.HGD patients that carry the TP53 mutation.
Metformin, a lipid metabolism modulating drug, was also shown to
inhibit proliferation of EAC cell lines,89 further supporting the plausibility of targeting speciﬁc pathways identiﬁed in the analysis and the
importance of patient stratiﬁcation based on TP53 mutational status.
Finally, epidemiological and limited preclinical data point to statins as
esophageal cancer inhibitors, in alignment with agents impacting
lipid metabolism holding promise in a subset of EACs.90–94

Signiﬁcant isoform-switched genes with direct interaction with
TP53 were also identiﬁed in this study, including RNF128,
KDM6B, and WRAP53 (Figure S3). WRAP53 has three separate
alternative start exons (1a, 1b, and 1g), which generate three
different transcripts of WRAP53 (a, b, and g).42 The precise function of WRAP53 is largely unknown; however, it was previously reported that the 50 UTR region of WRAP53a, located in exon 1a,
overlaps with the ﬁrst exon of TP53 and is a natural antisense of
TP53, inducing expression of both WT and MUT TP53.42 The other
two forms of WRAP53 (b and g) do not have exon regions that

Treatment of EAC cells with adapalene and APR-246 shows promising results inhibiting EAC cell viability in vitro, suggesting that targeting speciﬁc pathways or isoforms might offer novel therapeutic insights. Genetic manipulation of speciﬁc isoforms is required to
further explore the possibility of inhibiting EAC cell growth by modulating isoform expression levels. Development of synthetic spliceswitching oligonucleotides may also offer a future therapeutic direction as speciﬁc isoforms are better characterized and isoform-speciﬁc
inhibition showed potent results as targeted cancer therapies.95,96
Finally, survival analysis of patients stratiﬁed by expression levels of
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RNF128 and WRAP53 isoforms showed that expression of speciﬁc
isoforms could be used as prognostic markers to better predict patient
survival probability. Taken together, isoform switching analysis may
provide novel insights for the identiﬁcation of prognostic markers
and inform new potential therapeutic targets for EAC.

MATERIALS AND METHODS
RNA-seq and analysis of esophageal patient tissues

RNA was isolated from 57 esophageal tissues derived from 46 patients
undergoing esophagectomy following a diagnosis of EAC or HGD at
the University of Michigan as previously described.27,97 Signed
informed consent was obtained from each patient and all procedures
were consistent with the protocol submitted and approved by the
institutional review board. Tissue samples were collected from the
tumor or within a 6 cm of the surrounding area. Histopathology of
patient samples was characterized and conﬁrmed by two independent
pathologists. Patient tissues were categorized based on histopathology
into the following groups: BE with metaplasia (n = 6) or LGD (n = 19)
combined and referred to as BE.LGD (n = 25), BE with HGD based on
>40% HGD and referred to as BE.HGD (n = 21), and EAC (n = 11)
prior to RNA isolation. Total RNA was extracted using standard TRIzol methodology and all isolates had RNA integrity number greater
than 7.0. Strand-speciﬁc RNA-seq library preparation and sequencing
were performed at the University of Michigan Advanced Genomics
Core, using the Illumina HiSeq 100-base pair paired-end sequencing
platform. Quality control and adapter trimming were performed using Qiagen CLC Genomics Workbench 21.0 (https://digitalinsights.
qiagen.com/). After processing, the average read count per sample
was 72 million (range: 40–149 million, median: 63 million). RNA
quantiﬁcation and differential gene expression analysis were performed using Kallisto (version 0.46.2, 100 bootstraps with pseudoalignment saved) and Sleuth (version 0.30.0).98,99 On average, 83%
to 90% of read fragments were pseudoaligned per sample. Gencode
Human Release 34 (GRCh38.p13) was used as the gene and transcript
annotation source in the analysis, which contains 59,667 genes and
228,116 gene transcripts. Likelihood-ratio tests were used to determine signiﬁcantly differently expressed genes by comparison groups
and the Benjamini-Hochberg-adjusted FDR was applied to the analysis. Genes with p-value and FDR less than 0.05 were considered signiﬁcant. Sequence ﬁles are deposited to the NCBI Gene Expression
Omnibus (GEO:GSE193946) using the protocol approved by the
institutional review board. TP53 mutation analysis on patient samples
was performed using the PlexSeq process by PlexSeq Diagnostics
(Cleveland, OH). The lollipop plot of TP53 mutation was generated
using MutationMapper in cBioPortal.100,101 Differentially expressed
RBPs were identiﬁed using the result from Sleuth and the list of
known human RBPs was acquired from a previously published
study.102
Identification of isoform switching events

Identiﬁcation of isoform switching events was performed in R (version
4.1.1) using the IsoformSwitchAnalyzeR package (version 1.14.1).18,103
Kallisto was used to quantify transcript abundance, which was imported to the package, followed by ORF prediction and isoform switch

testing using an embedded function using the DEXSeq package.104–107
Isoform switching testing was performed by calculating the isoform
fraction (IF) deﬁned as the fraction of gene expression originating
from each associated isoform, and the differential isoform fraction
(dIF) value was subsequently determined by calculating the difference
of IF values between two conditions of interest. Several external analyses
were performed to predict functional consequences associated with isoform switching, including prediction of coding potential (CPAT),108
coding domains (Pfam),109 signal peptides (SignalP),110 intrinsically
disordered regions (IUPred2A),111 and sensitivity to nonsense-mediated decay.18,105,112,113 Results from external analyses were combined
with isoform switching testing to identify isoform switch events
with predicted functional consequences.18 Results were ﬁltered using
an absolute dIF cutoff at 0.1 and FDR cutoff at 0.05. Alternative splicing
analysis and genome-wide enrichment analysis were also performed.18,103,105 Volcano plots were generated using an embedded
function in the package and the dot plots were generated using ggplot2
(version 3.3.5) in R.18,114 The Venn diagram was generated using InteractiVenn.115 Isoform switching plots were generated directly by the
IsoformSwitchAnalyzeR package. ENSEMBL transcript IDs on the isoform switching plots were matched to the corresponding transcript
names. The overlapping region between WRAP53 isoforms and TP53
was identiﬁed using NCBI BLAST.116
Gene and isoform functional analysis

Comprehensive expression analysis was performed using the list
of genes/transcripts that showed signiﬁcant isoform switching
events. The gene names of statistically signiﬁcant (|dIF| R 0.1 and
FDR %0.05) isoform switches for comparison groups of interest
were uploaded and analyzed in Metacore and Cortellis Solution software (https://clarivate.com/products/metacore/, Clarivate Analytics,
London, UK). The Enrichment Analysis, Metabolic Network, GO
Molecular Function, and GO Localization tools were used to identify
enriched pathways, networks, and processes that were altered in each
comparison group. Signiﬁcance was calculated by using the hypergeometric test and the default Metacore database with Homo sapiens as
the background for each analysis. All p-value and FDR signiﬁcant
Pathway Maps, Process Networks, Diseases, GO Processes, Metabolic
Networks, GO Molecular Functions, and GO Localizations for each
comparison were exported for further analysis. Protein interactions
between identiﬁed genes and TP53 were predicted using the
STRING database (version 11.5) with minimum required interaction
score set to medium conﬁdence (0.400) and max number of interactors to show set to query proteins only.117 TP53 was added to the list
of proteins identiﬁed from isoform-switched genes and used as input
for STRING protein interaction prediction.
Gene-level GSEA

Gene-level GSEA analysis was performed as previously described.118
In short, ranking scores of each gene were calculated using the results
of differential gene expression analysis and saved as a ranked list ﬁle.
The ﬁle was imported to GSEA software (version 4.2.2; Broad Institute, Cambridge, MA) and analysis was performed using GO gene
sets in the Molecular Signatures Database with 1,000 permutations,
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max and min size set to 500 and 15, respectively.119–124 Leading-edge
genes of each identiﬁed pathway, which were genes that contributed
the most to the enrichment, were extracted from GSEA results. The
heatmap and bar plots were generated using ComplexHeatmap
(version 2.12.0) and ggplot2, respectively in R.114,125 The heatmap
was plotted using z-score-transformed transcripts per million
(TPM) values of leading-edge genes.

MiniMax Imaging Cytometer (Molecular Devices, San Jose, CA).
Following the initial ﬂuorescence reading for determining viability, cells
were replenished with fresh media and incubated for another 48 h to
determine whether cells recovered upon drug removal. Calcein-AM
staining was similarly used to quantify recovery of viability across
drug concentrations.
Statistical analysis

Isoform expression determination via quantitative reversetranscriptase PCR

cDNA for the qRT-PCR experiment was generated using the HighCapacity cDNA Reverse Transcription Kit (ThermoFisher Scientiﬁc,
Waltham, MA), following the manufacturer’s instructions, from
RNA extracted from isolated patient samples. qRT-PCR was performed on 50 ng cDNA from BE.LGD (n = 9) and BE.HGD (n =
11) patient samples using SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA) with CFX Connect
Thermo Cycler (Bio-Rad Laboratories), following the manufacturer’s instructions. Primer sequences for KRAS isoforms and
GAPDH were acquired from previously published studies and
primers for RNF128 isoforms, TRIM29 isoforms, and HPRT were
designed using NCBI Primer-BLAST (Table S11).126–128 Primers
were ordered from Euroﬁns Scientiﬁc (Louisville, KY). Relative isoform expression was quantiﬁed against housekeeping genes
(GAPDH and HPRT) and isoform fraction was calculated by
dividing relative isoform expression by the total relative expression
of both isoforms in a condition.

Survival analysis and calculation of statistical signiﬁcance for
viability data were performed using GraphPad Prism v9.1.0
(GraphPad Software, San Diego, CA). p-values % 0.05 were considered signiﬁcant unless otherwise noted. Survival analysis was
performed on patients stratiﬁed by expression levels of speciﬁc transcripts. Patients were divided into tertiles based on TPM expression
values for each transcript with upper compared with lower tertiles
used to investigate survival differences using the Gehen-BreslowWilcoxon test. One-tail two-sample t-tests were applied to determine signiﬁcant changes in isoform fraction between BE.LGD and
BE.HGD patient samples in qRT-PCR experiments and statistically
signiﬁcant differences in cellular viability assay were determined by
using a one-way ANOVA with Tukey’s post hoc multiple comparisons test.
Data availability statement

RNA-sequencing ﬁles generated and analyzed during this study are
available in the NCBI Gene Expression Omnibus (GEO: GSE193946).

SUPPLEMENTAL INFORMATION
Cell culture

OE33 and JH-EsoAd1 (JHAD1) cells were cultured in RPMI 1640
medium containing 2.0 mM L-glutamine, 104 units/mL penicillin,
104 mg/mL streptomycin, 1 mM sodium pyruvate, and 10% fetal
bovine serum (FBS). Cell culture reagents were acquired from either
ThermoFisher Scientiﬁc or Sigma-Aldrich (St. Louis, MO). All cells
were incubated at 37 C with 5% CO2 and maintained as monolayers.
The OE33 cell line was obtained from the European Collection of
Authenticated Cell Cultures (ECACC, Wiltshire, UK) and the
JHAD1 cell line was kindly shared by Dr. James R. Eshleman (Johns
Hopkins University, Baltimore, MD).

Supplemental information can be found online at https://doi.org/10.
1016/j.omtn.2022.08.018.
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Cellular viability assay

OE33 and JHAD1 cells were seeded in black-walled clear bottom
96-well plates at a concentration of 6,000 and 8,000 cells/well, respectively. Following overnight incubation, cells were treated with adapalene (1.0–2.0 mM; Tocris Bioscience, Bristol, UK) or APR-246
(10–40 mM; Cayman Chemical Company, Ann Arbor, MI). Treatments
were prepared by diluting the stock solution to the desired experimental
concentrations in RPMI 1640 medium containing 2.0 mM
L-glutamine, 104 units/mL penicillin, 104 mg/mL streptomycin, 1 mM
sodium pyruvate, and 5% FBS. Vehicle control was 0.08% DMSO
diluted in the same medium. To determine cell viability, OE33 and
JHAD1 cells were stained using Calcein-AM (ThermoFisher Scientiﬁc)
at 48 and 72 h post-drug treatment as previously reported.129 Brieﬂy,
ﬂuorescent images and readings were acquired using the SpectraMax
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